首页> 外文期刊>Endocrinology and Metabolism Clinics of North America >Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.
【24h】

Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.

机译:绝经后激素治疗和乳腺癌风险:现状和未解决的问题。

获取原文
获取原文并翻译 | 示例
           

摘要

Many women take hormone therapy (HT) for menopausal symptom relief. Studies have tried to clarify whether various factors can modify the risk of HT, such as the age at initiation, dose, duration, or type of HT, or characteristics of the individual, such as family history or body mass index. The relative risks of breast cancer associated with HT across various subgroups of women should be considered similar, but absolute risks can vary significantly among women and this may inform individual decision making. For breast cancer survivors, systemic HT should be discouraged.
机译:许多妇女采用激素疗法(HT)来缓解更年期症状。研究试图阐明各种因素是否可以改变HT的风险,例如开始时的年龄,剂量,持续时间或HT类型,或个体特征,如家族病史或体重指数。各个亚组女性与HT相关的乳腺癌的相对风险应被认为是相似的,但是女性的绝对风险可能存在显着差异,这可能会为个体决策提供依据。对于乳腺癌幸存者,不建议全身性HT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号